AbbVie acquires Novo Holdings portfolio company Syndesi
Syndesi Therapeutics (Syndesi), a portfolio company of international life sciences investor Novo Holdings, has been acquired by AbbVie for up to USD1 billion in total deal value with USD130 million upfront. Syndesi was created in 2018 as the result of a close collaboration between Novo Seeds, the company creation arm